AZD3470 as Monotherapy or in Combination with Anticancer Agent(s) in Participants With Haematologic Malignancies.

Trial Identifier: D9971C00001
Sponsor: AstraZeneca
Start Date: January 2024
Primary Completion Date: April 2029
Study Completion Date: April 2029
Condition: Hodgkin's lymphoma; Lymphoma; Non-Hodgkin's Lymphoma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Fitzroy, AU, 3065
AU Nedlands, AU, 6009
CN Beijing, CN, 100191
CN Guangzhou, CN, 510060
CN Shanghai, CN, 20032
DE Berlin, DE, 12203
DE Erlangen, DE, 91054
DE Köln, DE, 50937
DE Würzburg, DE, 97080
ES L'Hospitalet de Llobregat, ES, 08908
ES Madrid, ES, 28041
FR Creteil, FR, 94010
FR Lille, FR, 59000
FR PIERRE BENITE, FR, 69310
FR Villejuif Cedex, FR, 94805
GB Manchester, GB, M20 4BX
GB Oxford, GB, OX3 7LE
IT Alessandria, IT, 15100
IT Bologna, IT, 40138
IT Milano, IT, 20141
JP Bunkyo-ku, JP, 113-8677
JP Koto-ku, JP, 135-8550
KR Seoul, KR, 06351
KR Seoul, KR, 03080
US, CA Duarte, CA, US, 91010
US, FL Miami, FL, US, 33136
US, MA Boston, MA, US, 02215
US, NY New York, NY, US, 10016
US, PA Philadelphia, PA, US, 19104
US, TX Houston, TX, US, 77030